{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-312030","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2022-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.293542+00:00","generated_at":"2026-06-20T22:47:33.875992+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"KalVista raises ~$58M in registered direct offering of 9.48M shares at $6.00/share plus warrants","bullets":["9,484,199 shares at $6.00 per share, plus pre-funded warrants for 182,470 shares at $5.999 each.","Net proceeds expected ~$58M for clinical trials, commercial development, R&D, and working capital.","Offering closes Dec 28, 2022; post-closing shares outstanding ~34.1M (dilution of ~9.7M shares).","No underwriter; securities offered under existing shelf registration (File No. 333-256378)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-312030","json":"https://secwatch.observer/filing/0001193125-22-312030.json","markdown":"https://secwatch.observer/filing/0001193125-22-312030.md","text":"https://secwatch.observer/filing/0001193125-22-312030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312522312030/0001193125-22-312030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312522312030/d420223d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T22:47:33.875992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2444abb4a5c8e068e1e57fea2f545d262b95a516","claim":"KalVista Pharmaceuticals, Inc. entered into Subscription Agreements with certain purchasers valued at approximately $58 million (effective 2022-12-23).","evidence_excerpt":"On December 23, 2022, KalVista Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (collectively, the “Subscription Agreements”) with certain purchasers, pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Offering”) (i) an aggregate of 9,484,199 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 182,470 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000119312522312030/0001193125-22-312030-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers"},{"label":"Value","value":"approximately $58 million"},{"label":"Effective","value":"2022-12-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}